Letybo
Letybo is a U.S.-approved botulinum toxin type A product from Hugel. Its U.S. nonproprietary name is letibotulinumtoxinA-wlbg. In the United States, Letybo is tied to aesthetic glabellar-line labeling in adults.
Letybo connects the U.S. brand map to Hugel’s Korea-origin toxin portfolio. It sits near Jeuveau in market interpretation because both products connect Korean manufacturing with U.S. aesthetic-market entry, but each has its own company, label, formulation, and unit system.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| U.S. brand | Letybo |
| Nonproprietary name | LetibotulinumtoxinA-wlbg |
| Toxin type | Botulinum toxin type A |
| Manufacturer / company context | Hugel |
| Related portfolio names | Botulax and other regional names in Hugel materials |
| Comparison anchors | Jeuveau, Botox, Dysport, Xeomin, Daxxify |
U.S. Label Context
Section titled “U.S. Label Context”FDA materials list Letybo approval on February 29, 2024. The U.S. prescribing information describes Letybo as letibotulinumtoxinA-wlbg for injection, supplied as a lyophilized powder for intramuscular use after reconstitution.
The U.S. indication is temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. Other countries, names, or portfolio references require separate local product information.
Market Interpretation
Section titled “Market Interpretation”Hugel’s toxin portfolio includes names such as Botulax and Letybo. Those names are useful for mapping company strategy and regional commercialization, but they should not be collapsed into a single global label.
Letybo units are product-specific. They should not be treated as convertible to Botox, Dysport, Xeomin, Jeuveau, Daxxify, or any other toxin product.
Graph Connections
Section titled “Graph Connections”Hugel supplies the company and manufacturing context. Jeuveau is the nearest U.S. comparison point among Korea-origin type A products, while botulinum toxin type A provides the shared serotype context.